Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global ...
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...
Arvinas (ARVN) stock is in focus as the company and Pfizer (PFE) sell global rights to their breast cancer drug, Verzenio, to ...
Pfizer's acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth. Click here to read why I rate ...
Pfizer and Arvinas have landed a buyer for the newly approved breast cancer med Veppanu, selling an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and potentially hundreds ...
The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...
Arvinas and Pfizer have chosen Rigel Pharmaceuticals to bring their recently approved breast-cancer drug Veppanu to market.
Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results